ILS Bhubaneswar official sources said the bio-storage sites will use the clinical samples for research and development purposes in their respective institute. In addition, they can share the samples with academia, industry and commercial entities involved in the development of diagnostics, therapeutics and vaccines after reviewing the purpose of the request and securing the benefits of the country.
“While it is important to provide an early diagnosis and treatment to all infected individuals, it is also important to promote research and development for greater public health benefit,” said sources from Indian Council of Medical Research (ICMR).
The council currently said there is no structured mechanism for collecting and storing these valuable clinical samples. Therefore, it is important to create designated bio databases for collection,
storage and maintenance of clinical trials of Covid-19 patients. The tests will be a valuable resource for research and development-related activities to understand the early predictors of the severity of the disease, the immunopathogenesis of the disease, it added.
ILS Bhubaneswar Director Ajay Kumar Parida said access to various types of clinical trials from Covid-19 patients is required for the development and validation of new diagnostics, therapeutic treatment and vaccines. These repositories have been mandated for the collection, storage and maintenance of clinical specimens such as oropharyngeal swab (nasal swab), nasopharyngeal swab (nasal swab), bronchoalveolar lavage, sputum, blood, urine and stools in Covid-19 patients, I added.
Balaram Bhargav, Director General of the ICMR, has already requested all states to grant access to clinical trials of Covid-19 patients through designated Covid hospitals for greater public health benefit.
ILS Bhubaneswar has started Covid-19 testing since April and conducted almost 25,000 tests so far. “These designated biodata databases will develop uniform standard procedures for sample collection, transport, allocation, storage and sharing. The purpose of sharing clinical specimens in each bio storage site and their intended use will be examined by the National Regulatory Committee and the Institutional Human Ethics Committee,” said Parida.
Pradipta Kumar Mohapatra, Additional Chief Secretary, Department of Health and Family Welfare said this is very good news for Odisha and ILS Bhubaneswar. “We will fully support this initiative,” I added.